Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

附录：转移性低危透明细胞肾细胞癌伴NOTCH突变患者，在接受双重免疫阻断治疗后出现超进展，随后使用卡博替尼治疗后获得缓解。